Navigation Links
Genesis Biopharma Issues Letter To Shareholders
Date:5/21/2012

LOS ANGELES, May 21, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.genesis-biopharma.com.  In addition, on May 15, 2012, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three months ended March 31, 2012 on Form 10-Q.  The Form 10-Q includes unaudited interim consolidated financial statements containing the information highlighted below, as well as additional information regarding the Company.  The Form 10-Q is available at www.sec.gov or www.genesis-biopharma.com

Dear Shareholders:

The past months have been a productive and exciting time for Genesis Biopharma as we worked diligently to advance the clinical development of our targeted cancer immunotherapy, a ready-to-infuse autologous cell therapy ("ACT") utilizing tumor infiltrating lymphocytes ("TILs") for the treatment of patients with Stage IV metastatic melanoma.  ACT is based on a physician-sponsored investigational therapy currently available at the National Cancer Institute ("NCI"), MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for this same indication. 

During the fourth quarter of 2011, we were pleased to announce our Patent License Agreement with the National Institutes of Health ("NIH"), under which Genesis Biopharma was granted a non-exclusive worldwide license to 43 patents and patent applications.  These include nine U.S. issued patents, 13 U.S. patent applications, and 21 foreign corresponding patents and patent applications relating to adoptive cell therapy using autologous TILs for the treatment of certain cancers. 

W
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
2. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
5. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
6. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
8. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. Genesis Biopharma Names David Voyticky to Board of Directors
11. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ... and Chief Executive Officer, will present at the Rodman & ... New York on Tuesday, Sept. 9, 2014 ... archived webcast of the presentation will be accessible by visiting ... Events" section. About Oncothyreon ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $2.1 million. The orders consist of three large odour control ... . "These orders are consistent with the ... Peter Bruijns , President and CEO. "After a difficult ... we are now beginning to see sales growth. Our lower ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... DCGN ) announced that on February 2, 2009, ... (the "Panel") stating that the Panel,will transfer the listing ... the Nasdaq Capital Market, effective at the open of ... Capital Market, which is,one of the three market tier ...
... Health,Inc. (Nasdaq: GHDX ) today reported financial results ... 31, 2008. , Total revenue for ... $19.3 million in the fourth quarter of 2007. Product ... in the fourth,quarter of 2008, an increase of 60 percent, ...
... Abt Associates announced that Ricky Takai, Ph.D., has ... brief orientation to the firm, Dr. Takai will become ... 2009. Dr. Takai brings his more than 20 ... evaluation studies in the field of education to the ...
Cached Biology Technology:deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 2deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates 2
(Date:9/2/2014)... by researchers at the University of Warwick in the ... published in the Journal Early Human Development , ... in hospital after birth and the use of mechanical ... preterm children. , Mathematic abilities are crucial for lifelong ... very preterm children. Earlier studies of children who are ...
(Date:9/2/2014)... breast milk is considered the most ideal source ... played a critical role in the evolution and ... human milk contains a large number of bacterial ... phenomenon comes as no surprise to scientists and ... is considered to be the result of co-evolutionary ...
(Date:9/2/2014)... In the battle between our immune systems and ... bacteria-killing viruses known as phages. In a new study, ... Health, Haiti,s National Public Health Laboratory, and elsewhere, report ... their virulence in order to survive. Importantly, the study ... cholera,s mutational escape from phage predation occurs during human ...
Breaking Biology News(10 mins):Mechanical ventilation a key indicator for pre-term children's math problems 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... Medicine (BUSM) have brought attention to the potential health impacts ... brown seaweed soup. Seaweed is a known source of dietary ... on the iodine content in Korean seaweed soup. Written ... Thyroid and published online, the authors discuss the adverse ...
... investigation into the underlying causes of sudden cardiac death (SCD) ... the United States researchers have discovered a variation in ... increase in a person,s risk of SCD. The new ... region along the genome containing three genes previously unknown to ...
... useful strategy for helping prevent the development of panic and ... with an intense fear of the nausea, racing heart, dizziness, ... known as "high anxiety sensitivity" reacted with less anxiety ... high levels of physical activity, said researchers at Southern Methodist ...
Cached Biology News:BUSM researchers urge awareness of dietary iodine intake in postpartum Korean-American women 2Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death 2Study: People at risk for panic buffered from stressor by high levels of physical activity 2Study: People at risk for panic buffered from stressor by high levels of physical activity 3
... For nucleofection of optimized cell lines in ... the nucleofection parameters. Nucleofector Kits are only ... Different cell lines can be transfected with ... are given in brackets in percent (Efficiency ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
B-FABP (FL-132)...
... a highly purified preparation of the catalytic ... which recognizes the identical cleavage site as ... enzymatic activity (1). Novagen&'s enzyme is produced ... the highest activity available, and is qualified ...
Biology Products: